SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 12.46 |
| Enterprise Value ($M) | 12.46 |
| Book Value ($M) | 0.00 |
| Book Value / Share | 0.00 |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | 0.00 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -8.65 |
| Return on Equity (ROE) | -20.21 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Bailey Gregory | 30.70 | 378.44 | |
| 13D/A | Mellon James | 16.70 | ||
| 13G/A | Armistice Capital, Llc | 4.99 | -97.23 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 23,244 | 82,110 | 28.31 | |
| 10,290 | 73,014 | 14.09 | |
| 20,944 | 190,955 | 10.97 | |
| 10,843 | 51,552 | 21.03 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PROK – ProKidney Corp. | PRPH – ProPhase Labs, Inc. |
| PRQR – ProQR Therapeutics N.V. | PTIX – Protagenic Therapeutics, Inc. |
| PTPI – Petros Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io